Skip to main content
OpenTrials
Completed

NCT Number: NCT02566356

Adult Study Oxytocin - fMRI

In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia. Such research is a necessary first step towards identifying whether intranasal oxytocin administration can serve as an adjunct treatment for social impairments in schizophrenia.

Aim 1: To examine the effects of exogenous oxytocin on patterns of neural activation as measured by fMRI during a well-characterized affect-labeling task in patients with recent-onset schizophrenia and healthy comparison subjects.

Hypothesis A: Patients will exhibit amygdalar hyperactivity and PNS hypo-activity when passively viewing faces, which will be normalized by administration of oxytocin.

Hypothesis B: Patients will exhibit hypo-activity of the vPFC when affectively labeling faces and this hypo-activity will be normalized by oxytocin administration.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Early Phase 1

Primary location

San Francisco Veterans Affairs Medical Center, San Francisco, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for Patients:

  • Male
  • SCID-IV confirmed diagnosis of schizophrenia or schizoaffective disorder
  • Clinically stable
  • No changes to medications for the past week

Inclusion criteria

for Healthy Controls:

  • Male
  • SCID-IV confirmed no diagnosis of a current Axis I disorder within the last year

Exclusion criteria

for Patients and Healthy Controls:

  • Meeting criteria for current substance abuse or dependence or illicit drug use within the last month (nicotine use is acceptable) as determined by a Urine Toxicology Drug Screening
  • Any illness that affects the nasal passages and impairs the delivery of a nasal spray
  • Presence of any neurological or significant medical disorder, including medical illnesses that could interfere with physiological recording such as cardiac arrhythmias
  • A pacemaker, extensive dental work, or any magnetic metal implants and upper body tattoos
  • Pregnancy
  • Claustrophpbia
  • Hearing difficulties
  • A history of seizures
  • Failure to receive a passing score on the reading test

Additional Exclusion Criteria for Patients and Healthy Controls:

  • Taking any psychotropic medication or any medication that affects the autonomic or cardiovascular systems.
  • Schizophrenia or other psychotic disorder in a first degree relative
  • Failure to receive a passing score on the MOCA

Treatment and study plan

Oxytocin

Drug

40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.

Other names: Syntocinon

Saline Nasal Spray

Drug

40 IU of the saline nasal spray will be administered once at the beginning of the visit.

Other names: Placebo

Primary outcomes

  1. Change in fMRI neural activation patterns

    Time frame: 2-days at least 1-week apart

    During tasks in which participants will see and hear various stimuli, investigators will measure the change in neural activity in the medial prefrontal cortex and the temporoparietal junction between placebo and oxytocin testing days using the fMRI 3T Siemens Skyra scanner.

Secondary outcomes

  1. Quality of Life Scale (QLS)

    Time frame: 1 day

    The QLS is a 21-item clinical rating scale where the interviewer rates the participant's responses on a scale of 1-6 where 6 indicates no impairment. In the fMRI study an abbreviated version of the QLS is used that includes 9 of the 21 items. The 9 items are each derived from the sections examining interpersonal relations, occupational role functioning, intrapsychic foundations, and common objects.

  2. Social Functioning Scale (SFS)

    Time frame: 1 day

    The SFS is designed to assess a subject's social skills and performance, and to measure functions that are of importance for schizophrenic patients. It is a 79-item scale completed by the subject.

  3. UCLA Loneliness Scale

    Time frame: 1 day

    The UCLA Loneliness Scale assesses the loneliness level of participants. It is a 20-item scale where responses are measured from O ("I often feel this way") to N ("I never feel this way").

  4. Experiences in Close Relationships - Relationship Structures (ECR-RS)

    Time frame: 1 day

    The ECR is used to evaluate the construct of adult attachment. The scale involves 36 itemized statements split into four parts, each part referring to a different attachment figure. Participants rank each item using a 7-point likert scale.

  5. Parental Bonding Instrument (PBI)

    Time frame: 1 day

    The PBI measures fundamental parenting styles as perceived the child. The questionnaire is retrospective in that it asks the adult participant to answer the questions based on how they remember their parents to be during up until they were 16 years old. The measure is completed for both mothers and fathers separately. There are 25 questions where half the questions are focused on how the parent cared for them and half are focused on how the parents protected them. A likert scale is used to measure responses where 1 is agree (i.e. very like) and 4 is disagree (i.e. very dislike).

  6. Premorbid IQ test (AmNART)

    Time frame: 1 day

    The American National Adult Reading Test (AMNART) is an instrument used to estimate premorbid verbal IQ in adults. Participants are shown 45 words one at a time and are asked to read the word aloud. The scorer then writes 0 if the participant read the word incorrectly or 1 if the pronunciation is correct.

  7. Childhood Trauma Questionnaire (CTQ)

    Time frame: 1 day

    The CTQ is a brief survey of 6 early traumatic experiences, including death, divorce, violence, sexual abuse, illness or other. The scale determines and assesses an individual's understanding of their childhood trauma, if applicable.

  8. Emotional Quotient Scale (EQS)

    Time frame: 1 day

    The EQ is a 60-item self-report questionnaire that is designed to measure empathy in adults. Participants use a 4 item likert scale to record their responses (1=definitely agree, 4= definitely disagree).

  9. Kinsey Scale

    Time frame: 1 day

    The Kinsey scale attempts to describe a person's sexual orientation using a scale from 0 (i.e. heterosexual) to 6 (i.e. homosexual).

  10. Socioeconomic Status (SES)

    Time frame: 1 day

    This assess participants' socioeconomic status through their educational level and occupational level using a scale from 1 (i.e. professional, higher executive level) to 7 (i.e. less than 7 years of school, unskilled employee). This scale is also used for the participants' primary and secondary caretakers.

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • San Francisco Veterans Affairs Medical Center

Registry information

Official study title

Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - fMRI

Acronym: ASO-fMRI

Important dates

Study start
2012
Primary completion
2017
Study completion
2017
First posted
Oct 2, 2015
Registry last updated
May 21, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.